

PANEL DISCUSSION: PATENTS ON BIOLOGICAL TARGETS

BIH Technology Transfer Seminar Series

29 February 2016 3pm – 5pm at MDC.C, Dendrit 2/3

**BERLIN
INSTITUTE
OF HEALTH**

Charité & Max Delbrück Center

Seminar Topics

A first step in the development of a new treatment for a disease is the identification of a biological target. In Academia planned publications demand a fast decision on whether and what should be patented at such an early stage. However, what can be patented around a biological target? What data is necessary to do so? What makes sense from an economical point of view? And what makes sense from the view-point of an Academic Institute? The planned panel discussion will address these questions.

AGENDA

3.00 pm

Dr. Ute Kilger (Patent Attorney, BOEHMERT & BOEHMERT)

From a patent attorney's perspective:

"Strategies to obtain patent protection for a biological target."

Dr. Klaus-Peter Döpfer (Director Biotechnology, European Patent Office)

From the EPO's perspective:

"What data is needed for a target patent?"

3.40 pm

Dr. Michael Karle (Technology Manager, Ascenion)

From Academia's perspective:

"What would be reasonable to patent – commercially?"

3.50 pm

Panel Discussion

Dr. Ute Kilger (BOEHMERT & BOEHMERT), **Dr. Klaus-Peter Döpfer** (Director Biotechnology, EPO), **Dr. Michael Karle** (Technology Manager, Ascenion), **Dr. Gunnar Plesch** (Head IP Department, Metanomics Health) and **Dr. Björn Timmerbeil** (Senior Counsel SANOFI / Global Intellectual Property Department)

We are looking forward to a vivid discussion with all participants.

VENUE

MDC Campus Berlin-Buch
MDC.C Communication Center
Seminar room: Dendrit 2/3

REGISTRATION

Please send an E-mail to

AT THE LATEST ON 24 FEBRUARY 2016

Maxi.Hiller@mdc-berlin.de



MDC

MAX-DELBROCK-CENTRUM
FÜR MOLEKULARE MEDIZIN
IN DER HELMHOLTZ-GEMEINSCHAFT